Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR

Journal of Thoracic Oncology

Volumn 8, Issue 9, 2013, Pages

  Berge, Eamon M ^a   Aisner, Dara L ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; BONE METASTASIS; CANCER STAGING; CASE REPORT; EXON; FEMALE; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSTICS; NOTE; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84883321412     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31829ceb8d     Document Type: Article

References (5)

1. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301-308.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3. Brandão EP, Pantarotto MG, Cruz M. A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose. J Thorac Oncol 2012;7:e32.
4. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
5. Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:45-51.